Boston Scientific Beats Q1 but Lowers Full-Year Guidance on EP and WATCHMAN Headwinds

Transcript intelligence

What changed

In Q1 FY2026, BSX delivered 9.4% organic revenue growth and adjusted EPS of $0.80, a 1.5% beat over the $0.79 consensus. Revenue of $5.20B exceeded estimates by 0.6%. The most significant change was the reduction in full-year guidance: organic growth was lowered to 6.5%-8% and adjusted EPS to $3.34-$3.41, driven by unexpected softness in electrophysiology, the WATCHMAN portfolio, and urology (only 1% organic growth). Management also announced the closure of the Valencia Technologies acquisition and confirmed a $2B share repurchase plan for Q2 within the $5B total program, even as the Penumbra acquisition awaits a shareholder vote. The stock surged roughly 9% on the earnings day but has since drifted approximately 13% lower, with the shares now trading at $45.38 versus the $75.45 analyst consensus target.

Guidance delta

Full-year organic revenue growth guidance was lowered to 6.5%-8% and adjusted EPS guidance was reduced to $3.34-$3.41. The guidance cut reflects three specific headwinds: (1) unexpected deceleration in electrophysiology, partly tied to the accelerated discontinuation of the POLARx cryoablation system following safety events; (2) WATCHMAN volume trends falling below expectations; and (3) urology weakness with only 1% organic growth, prompting new product launches and commercial hiring.

Key takeaways

• Q1 organic revenue grew 9.4% and adjusted EPS of $0.80 beat the $0.79 consensus by 1.5%.
• Full-year guidance was lowered to 6.5%-8% organic growth and $3.34-$3.41 adjusted EPS, citing EP, WATCHMAN, and urology headwinds.
• FARAPULSE PFA, WATCHMAN, and OPAL mapping portfolio continue to drive growth, particularly in the U.S. and APAC.
• Urology lagged at 1% organic growth, prompting new product launches including StoneSmart and commercial hiring.
• Valencia Technologies acquisition closed; Penumbra acquisition pending shareholder vote on May 7.
• Company plans $2B in share repurchases in Q2 within a $5B total buyback program.

Management priorities

• Launch third-generation FARAPULSE platform and FARAWAVE Ultra in H1 2027.
• Initiate IDE for FANAFLEX later this year with U.S. launch planned for 2028.
• Scale Seismic IVL for above- and below-knee applications in 2027.
• Roll out additional urology products including StoneSmart ecosystem and insulin urethroscope.
• Increase commercial investment for WATCHMAN and EP, and pursue further tuck-in acquisitions.
• Execute $2B share repurchase in Q2 while maintaining the $5B overall buyback program.